Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2) : A population-based study

Citadel J Cabasag; John Butler; Melina Arnold; Mark Rutherford; Aude Bardot; Jacques Ferlay; Eileen Morgan; Bjørn Møller; Anna Gavin; Charles H Norell; Samantha Harrison; Nathalie Saint-Jacques; Michael Eden; Brian Rous; Andy Nordin; Louise Hanna; Janice Kwon; Paul A Cohen; Alon D Altman; Lorraine Shack; Serena Kozie; Gerda Engholm; Prithwish De; Peter Sykes; Geoff Porter; Sarah Ferguson; Paul Walsh; Richard Trevithick; Dianne O'Connell; Freddie Bray; Isabelle Soerjomataram

doi:10.1016/j.ygyno.2019.12.047

Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2) : A population-based study

Citadel J Cabasag, John Butler, Melina Arnold, Mark Rutherford, Aude Bardot, Jacques Ferlay, Eileen Morgan, Bjørn Møller, Anna Gavin, Charles H Norell, Samantha Harrison, Nathalie Saint-Jacques, Michael Eden, Brian Rous, Andy Nordin, Louise Hanna, Janice Kwon, Paul A Cohen, Alon D Altman, Lorraine ShackSerena Kozie, Gerda Engholm, Prithwish De, Peter Sykes, Geoff Porter, Sarah Ferguson, Paul Walsh, Richard Trevithick, Dianne O'Connell, Freddie Bray, Isabelle Soerjomataram

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

489 Downloads (Pure)

Abstract

OBJECTIVE: The study aims to evaluate the differences in ovarian cancer survival by age and stage at diagnosis within and across seven high-income countries.

METHODS: We analyzed data from 58,161 women diagnosed with ovarian cancer during 2010-2014, followed until 31 December 2015, from 21 population-based cancer registries in Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Comparisons of 1-year and 3-year age- and stage-specific net survival (NS) between countries were performed using the period analysis approach.

RESULTS: Minor variation in the stage distribution was observed between countries, with most women being diagnosed with 'distant' stage (ranging between 64% in Canada and 71% in Norway). The 3-year all-ages NS ranged from 45 to 57% with Australia (56%) and Norway (57%) demonstrating the highest survival. The proportion of women with 'distant' stage was highest for those aged 65-74 and 75-99 years and varied markedly between countries (range:72-80% and 77-87%, respectively). The oldest age group had the lowest 3-year age-specific survival (20-34%), and women aged 65-74 exhibited the widest variation across countries (3-year NS range: 40-60%). Differences in survival between countries were particularly stark for the oldest age group with 'distant' stage (3-year NS range: 12% in Ireland to 24% in Norway).

CONCLUSIONS: International variations in ovarian cancer survival by stage exist with the largest differences observed in the oldest age group with advanced disease. This finding endorses further research investigating international differences in access to and quality of treatment, and prevalence of comorbid conditions particularly in older women with advanced disease.

Original language	English
Journal	Gynecologic Oncology
Early online date	28 Jan 2020
DOIs	https://doi.org/10.1016/j.ygyno.2019.12.047
Publication status	Early online date - 28 Jan 2020

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ygyno.2019.12.047Licence: Unspecified

Exploring_variations_in_ovarian_cancer_survival_by_age_and_stage_ICBP_SurvMark_2_A_population_based_study
Copyright 2020 Elsevier. This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Accepted author manuscript, 174 KBLicence: CC BY-NC-ND

Cite this

Cabasag, C. J., Butler, J., Arnold, M., Rutherford, M., Bardot, A., Ferlay, J., Morgan, E., Møller, B., Gavin, A., Norell, C. H., Harrison, S., Saint-Jacques, N., Eden, M., Rous, B., Nordin, A., Hanna, L., Kwon, J., Cohen, P. A., Altman, A. D., ... Soerjomataram, I. (2020). Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2) : A population-based study. Gynecologic Oncology. Advance online publication. https://doi.org/10.1016/j.ygyno.2019.12.047

@article{941ff60ce03e4556961aa69db6833677,

title = "Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2) : A population-based study",

abstract = "OBJECTIVE: The study aims to evaluate the differences in ovarian cancer survival by age and stage at diagnosis within and across seven high-income countries.METHODS: We analyzed data from 58,161 women diagnosed with ovarian cancer during 2010-2014, followed until 31 December 2015, from 21 population-based cancer registries in Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Comparisons of 1-year and 3-year age- and stage-specific net survival (NS) between countries were performed using the period analysis approach.RESULTS: Minor variation in the stage distribution was observed between countries, with most women being diagnosed with 'distant' stage (ranging between 64\% in Canada and 71\% in Norway). The 3-year all-ages NS ranged from 45 to 57\% with Australia (56\%) and Norway (57\%) demonstrating the highest survival. The proportion of women with 'distant' stage was highest for those aged 65-74 and 75-99 years and varied markedly between countries (range:72-80\% and 77-87\%, respectively). The oldest age group had the lowest 3-year age-specific survival (20-34\%), and women aged 65-74 exhibited the widest variation across countries (3-year NS range: 40-60\%). Differences in survival between countries were particularly stark for the oldest age group with 'distant' stage (3-year NS range: 12\% in Ireland to 24\% in Norway).CONCLUSIONS: International variations in ovarian cancer survival by stage exist with the largest differences observed in the oldest age group with advanced disease. This finding endorses further research investigating international differences in access to and quality of treatment, and prevalence of comorbid conditions particularly in older women with advanced disease.",

author = "Cabasag, \{Citadel J\} and John Butler and Melina Arnold and Mark Rutherford and Aude Bardot and Jacques Ferlay and Eileen Morgan and Bj{\o}rn M{\o}ller and Anna Gavin and Norell, \{Charles H\} and Samantha Harrison and Nathalie Saint-Jacques and Michael Eden and Brian Rous and Andy Nordin and Louise Hanna and Janice Kwon and Cohen, \{Paul A\} and Altman, \{Alon D\} and Lorraine Shack and Serena Kozie and Gerda Engholm and Prithwish De and Peter Sykes and Geoff Porter and Sarah Ferguson and Paul Walsh and Richard Trevithick and Dianne O'Connell and Freddie Bray and Isabelle Soerjomataram",

year = "2020",

month = jan,

day = "28",

doi = "10.1016/j.ygyno.2019.12.047",

language = "English",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

}

Cabasag, CJ, Butler, J, Arnold, M, Rutherford, M, Bardot, A, Ferlay, J, Morgan, E, Møller, B, Gavin, A, Norell, CH, Harrison, S, Saint-Jacques, N, Eden, M, Rous, B, Nordin, A, Hanna, L, Kwon, J, Cohen, PA, Altman, AD, Shack, L, Kozie, S, Engholm, G, De, P, Sykes, P, Porter, G, Ferguson, S, Walsh, P, Trevithick, R, O'Connell, D, Bray, F & Soerjomataram, I 2020, 'Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2) : A population-based study', Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2019.12.047

TY - JOUR

T1 - Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2) : A population-based study

AU - Cabasag, Citadel J

AU - Butler, John

AU - Arnold, Melina

AU - Rutherford, Mark

AU - Bardot, Aude

AU - Ferlay, Jacques

AU - Morgan, Eileen

AU - Møller, Bjørn

AU - Gavin, Anna

AU - Norell, Charles H

AU - Harrison, Samantha

AU - Saint-Jacques, Nathalie

AU - Eden, Michael

AU - Rous, Brian

AU - Nordin, Andy

AU - Hanna, Louise

AU - Kwon, Janice

AU - Cohen, Paul A

AU - Altman, Alon D

AU - Shack, Lorraine

AU - Kozie, Serena

AU - Engholm, Gerda

AU - De, Prithwish

AU - Sykes, Peter

AU - Porter, Geoff

AU - Ferguson, Sarah

AU - Walsh, Paul

AU - Trevithick, Richard

AU - O'Connell, Dianne

AU - Bray, Freddie

AU - Soerjomataram, Isabelle

PY - 2020/1/28

Y1 - 2020/1/28

N2 - OBJECTIVE: The study aims to evaluate the differences in ovarian cancer survival by age and stage at diagnosis within and across seven high-income countries.METHODS: We analyzed data from 58,161 women diagnosed with ovarian cancer during 2010-2014, followed until 31 December 2015, from 21 population-based cancer registries in Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Comparisons of 1-year and 3-year age- and stage-specific net survival (NS) between countries were performed using the period analysis approach.RESULTS: Minor variation in the stage distribution was observed between countries, with most women being diagnosed with 'distant' stage (ranging between 64% in Canada and 71% in Norway). The 3-year all-ages NS ranged from 45 to 57% with Australia (56%) and Norway (57%) demonstrating the highest survival. The proportion of women with 'distant' stage was highest for those aged 65-74 and 75-99 years and varied markedly between countries (range:72-80% and 77-87%, respectively). The oldest age group had the lowest 3-year age-specific survival (20-34%), and women aged 65-74 exhibited the widest variation across countries (3-year NS range: 40-60%). Differences in survival between countries were particularly stark for the oldest age group with 'distant' stage (3-year NS range: 12% in Ireland to 24% in Norway).CONCLUSIONS: International variations in ovarian cancer survival by stage exist with the largest differences observed in the oldest age group with advanced disease. This finding endorses further research investigating international differences in access to and quality of treatment, and prevalence of comorbid conditions particularly in older women with advanced disease.

AB - OBJECTIVE: The study aims to evaluate the differences in ovarian cancer survival by age and stage at diagnosis within and across seven high-income countries.METHODS: We analyzed data from 58,161 women diagnosed with ovarian cancer during 2010-2014, followed until 31 December 2015, from 21 population-based cancer registries in Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Comparisons of 1-year and 3-year age- and stage-specific net survival (NS) between countries were performed using the period analysis approach.RESULTS: Minor variation in the stage distribution was observed between countries, with most women being diagnosed with 'distant' stage (ranging between 64% in Canada and 71% in Norway). The 3-year all-ages NS ranged from 45 to 57% with Australia (56%) and Norway (57%) demonstrating the highest survival. The proportion of women with 'distant' stage was highest for those aged 65-74 and 75-99 years and varied markedly between countries (range:72-80% and 77-87%, respectively). The oldest age group had the lowest 3-year age-specific survival (20-34%), and women aged 65-74 exhibited the widest variation across countries (3-year NS range: 40-60%). Differences in survival between countries were particularly stark for the oldest age group with 'distant' stage (3-year NS range: 12% in Ireland to 24% in Norway).CONCLUSIONS: International variations in ovarian cancer survival by stage exist with the largest differences observed in the oldest age group with advanced disease. This finding endorses further research investigating international differences in access to and quality of treatment, and prevalence of comorbid conditions particularly in older women with advanced disease.

U2 - 10.1016/j.ygyno.2019.12.047

DO - 10.1016/j.ygyno.2019.12.047

M3 - Article

C2 - 32005583

SN - 0090-8258

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -

Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2) : A population-based study

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this